BR112017010238A2 - composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular - Google Patents
composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelularInfo
- Publication number
- BR112017010238A2 BR112017010238A2 BR112017010238-2A BR112017010238A BR112017010238A2 BR 112017010238 A2 BR112017010238 A2 BR 112017010238A2 BR 112017010238 A BR112017010238 A BR 112017010238A BR 112017010238 A2 BR112017010238 A2 BR 112017010238A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- fibrosis
- extracellular matrix
- fibroblast proliferation
- matrix deposition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title abstract 2
- 230000008021 deposition Effects 0.000 title abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 230000001594 aberrant effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 4
- 230000004761 fibrosis Effects 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000007838 tissue remodeling Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080784P | 2014-11-17 | 2014-11-17 | |
| US62/080,784 | 2014-11-17 | ||
| US14/943,752 | 2015-11-17 | ||
| US14/943,752 US10500249B2 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| PCT/US2015/061118 WO2016081475A1 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017010238A2 true BR112017010238A2 (pt) | 2018-02-06 |
Family
ID=55960752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010238-2A BR112017010238A2 (pt) | 2014-11-17 | 2015-11-17 | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10500249B2 (enExample) |
| EP (1) | EP3220943A4 (enExample) |
| JP (1) | JP2018501201A (enExample) |
| KR (1) | KR20170083063A (enExample) |
| CN (1) | CN107106650A (enExample) |
| AU (1) | AU2015350151A1 (enExample) |
| BR (1) | BR112017010238A2 (enExample) |
| CA (1) | CA2967621A1 (enExample) |
| MX (1) | MX2017006372A (enExample) |
| RU (1) | RU2017121090A (enExample) |
| SG (1) | SG11201703939XA (enExample) |
| WO (1) | WO2016081475A1 (enExample) |
| ZA (1) | ZA201703305B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050786A (zh) * | 2017-09-08 | 2020-04-21 | 百时美施贵宝公司 | 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21) |
| EP3692073A4 (en) | 2017-10-03 | 2021-05-26 | Cedars-Sinai Medical Center | METHOD OF TARGETING THE IMMUNE CHECK POINT PD1 SIGNAL PATH FOR TREATMENT OF LUNG FIBROSIS |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| CN110575540B (zh) * | 2018-06-07 | 2021-11-02 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
| CN113134116B (zh) * | 2020-01-20 | 2022-09-06 | 山东威高宏瑞医学科技有限公司 | 内镜微创手术用的填充组合物及填充制剂 |
| CN113952821A (zh) * | 2021-07-22 | 2022-01-21 | 上海安居乐环保科技股份有限公司 | 一种罐区装卸区废气综合治理方法及系统 |
| CN113730551B (zh) * | 2021-09-02 | 2022-11-25 | 徐州医科大学 | Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用 |
| CN118388635B (zh) * | 2024-06-24 | 2024-10-11 | 山东美瑞生物技术有限公司 | 一种提高皮肤修复功能的重组人源化胶原蛋白的制备方法 |
| CN118571492B (zh) * | 2024-08-02 | 2024-10-18 | 天津市胸科医院 | 基于组织边界影响的主动脉夹层患者并发症风险预测模型 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| DK172541B1 (da) | 1982-10-08 | 1998-12-07 | Glaxo Group Ltd | Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| DK0733059T3 (da) | 1993-12-09 | 2000-10-16 | Univ Jefferson | Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| DK1165050T3 (da) | 1999-04-05 | 2006-05-01 | Mannkind Corp | Fremgangsmåde til dannelse af fint pulver |
| ES2395096T3 (es) | 1999-06-29 | 2013-02-08 | Mannkind Corporation | Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| BRPI0514410A (pt) | 2004-08-23 | 2008-06-10 | Mannkind Corp | fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5 |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| ES2594281T3 (es) * | 2007-01-10 | 2016-12-19 | Purdue Research Foundation | Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos |
| NL1033850C2 (nl) | 2007-05-15 | 2008-11-18 | 3Force B V | Brandersysteem met voorgemengde branders en vlam-overdrachtsmiddelen. |
| DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
| CN102256613B (zh) * | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| US9327008B2 (en) * | 2008-12-10 | 2016-05-03 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| EP2575855A4 (en) * | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE |
| CN108014340A (zh) * | 2011-04-12 | 2018-05-11 | 莫伊莱麦屈克斯公司 | 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法 |
| WO2013134636A1 (en) * | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| US9750718B2 (en) * | 2012-12-12 | 2017-09-05 | The Charlotte-Mecklenburg Hospital Authority | Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity |
-
2015
- 2015-11-17 MX MX2017006372A patent/MX2017006372A/es unknown
- 2015-11-17 AU AU2015350151A patent/AU2015350151A1/en not_active Abandoned
- 2015-11-17 BR BR112017010238-2A patent/BR112017010238A2/pt not_active Application Discontinuation
- 2015-11-17 US US14/943,752 patent/US10500249B2/en not_active Expired - Fee Related
- 2015-11-17 JP JP2017526674A patent/JP2018501201A/ja active Pending
- 2015-11-17 EP EP15861651.6A patent/EP3220943A4/en not_active Withdrawn
- 2015-11-17 SG SG11201703939XA patent/SG11201703939XA/en unknown
- 2015-11-17 WO PCT/US2015/061118 patent/WO2016081475A1/en not_active Ceased
- 2015-11-17 KR KR1020177014506A patent/KR20170083063A/ko not_active Withdrawn
- 2015-11-17 CN CN201580062363.0A patent/CN107106650A/zh active Pending
- 2015-11-17 RU RU2017121090A patent/RU2017121090A/ru not_active Application Discontinuation
- 2015-11-17 CA CA2967621A patent/CA2967621A1/en not_active Abandoned
-
2017
- 2017-05-12 ZA ZA2017/03305A patent/ZA201703305B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017121090A (ru) | 2018-12-20 |
| SG11201703939XA (en) | 2017-06-29 |
| CN107106650A (zh) | 2017-08-29 |
| EP3220943A1 (en) | 2017-09-27 |
| ZA201703305B (en) | 2020-05-27 |
| RU2017121090A3 (enExample) | 2019-06-10 |
| MX2017006372A (es) | 2017-08-21 |
| JP2018501201A (ja) | 2018-01-18 |
| KR20170083063A (ko) | 2017-07-17 |
| US20160136234A1 (en) | 2016-05-19 |
| WO2016081475A1 (en) | 2016-05-26 |
| CA2967621A1 (en) | 2016-05-26 |
| AU2015350151A1 (en) | 2017-06-01 |
| EP3220943A4 (en) | 2018-08-01 |
| US10500249B2 (en) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NI201900119A (es) | Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| BR112017023904A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
| ECSP18073245A (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| BR112017007813A2 (pt) | composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose | |
| BR112018017240A2 (pt) | ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante? | |
| BR112016021000A2 (pt) | Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf) | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| MX387909B (es) | Tratamiento para la migra?a | |
| EA201892322A1 (ru) | Способ лечения или предупреждения остеоартрита | |
| BR112017016596A2 (pt) | composição farmacêutica para prevenir ou tratar a leucemia mieloide crônica, e método de prevenção ou tratamento da leucemia mieloide crônica de um sujeito | |
| MX2019001320A (es) | Composicion y uso de un peptido. | |
| BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
| BR112017017064A2 (pt) | composição farmacêutica para prevenir ou tratar câncer, e uso do composto de fórmula i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |